Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Effect of beta-glucuronidase on urinary benzodiazepine concentrations determined by fluorescence polarization immunoassay

Simonsson, Per LU ; Lidén, Anders and Lindberg, Stellan (1995) In Clinical Chemistry 41(6 Pt 1). p.920-923
Abstract
In samples from patients treated with oxazepam, beta-glucuronidase increased the immunoreactivity of urinary benzodiazepines analyzed by fluorescence polarization immunoassay (FPIA). Increasing concentrations of beta-glucuronidase added to samples from drug-free controls did not influence the results. In the absence of beta-glucuronidase, 22 of 35 samples from patients undergoing detoxification gave positive results at a cutoff concentration of 200 micrograms/L. Pretreatment with beta-glucuronidase increased the number of drug-positive samples to 33. The drug-negative samples were obtained from two patients who had been oxazepam-free for at least 1 week. Thus, beta-glucuronidase can be used to increase the sensitivity of the urinary... (More)
In samples from patients treated with oxazepam, beta-glucuronidase increased the immunoreactivity of urinary benzodiazepines analyzed by fluorescence polarization immunoassay (FPIA). Increasing concentrations of beta-glucuronidase added to samples from drug-free controls did not influence the results. In the absence of beta-glucuronidase, 22 of 35 samples from patients undergoing detoxification gave positive results at a cutoff concentration of 200 micrograms/L. Pretreatment with beta-glucuronidase increased the number of drug-positive samples to 33. The drug-negative samples were obtained from two patients who had been oxazepam-free for at least 1 week. Thus, beta-glucuronidase can be used to increase the sensitivity of the urinary benzodiazepine FPIA without reducing the specificity of the method. (Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical Chemistry
volume
41
issue
6 Pt 1
pages
920 - 923
publisher
American Association for Clinical Chemistry
external identifiers
  • pmid:7768013
  • scopus:0028978014
ISSN
0009-9147
language
English
LU publication?
yes
id
3d6fac71-7947-4aaf-bd75-634345faa141 (old id 1109585)
alternative location
http://www.clinchem.org/cgi/reprint/41/6/920
date added to LUP
2016-04-01 11:55:05
date last changed
2021-01-03 04:25:49
@article{3d6fac71-7947-4aaf-bd75-634345faa141,
  abstract     = {{In samples from patients treated with oxazepam, beta-glucuronidase increased the immunoreactivity of urinary benzodiazepines analyzed by fluorescence polarization immunoassay (FPIA). Increasing concentrations of beta-glucuronidase added to samples from drug-free controls did not influence the results. In the absence of beta-glucuronidase, 22 of 35 samples from patients undergoing detoxification gave positive results at a cutoff concentration of 200 micrograms/L. Pretreatment with beta-glucuronidase increased the number of drug-positive samples to 33. The drug-negative samples were obtained from two patients who had been oxazepam-free for at least 1 week. Thus, beta-glucuronidase can be used to increase the sensitivity of the urinary benzodiazepine FPIA without reducing the specificity of the method.}},
  author       = {{Simonsson, Per and Lidén, Anders and Lindberg, Stellan}},
  issn         = {{0009-9147}},
  language     = {{eng}},
  number       = {{6 Pt 1}},
  pages        = {{920--923}},
  publisher    = {{American Association for Clinical Chemistry}},
  series       = {{Clinical Chemistry}},
  title        = {{Effect of beta-glucuronidase on urinary benzodiazepine concentrations determined by fluorescence polarization immunoassay}},
  url          = {{http://www.clinchem.org/cgi/reprint/41/6/920}},
  volume       = {{41}},
  year         = {{1995}},
}